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Summary 
 
Shiga toxin-producing E. coli (STEC) are associated with human illness and are 
defined by the presence of phage encoded Shiga toxin genes. While a relatively rare 
cause of gastrointestinal illness, they have potential to cause severe illness including 
bloody diarrhoea and Haemolytic Ureamic Syndrome (HUS), a serious and life 
threatening condition affecting the blood and kidneys and the most common cause 
of acute renal failure in children in the UK. The main reservoir for STEC is cattle and 
transmission can occur through direct or indirect contact with animals, consumption 
of contaminated food or water and through person to person spread. 
 
STEC first emerged as a pathogen of concern in the early 1980’s and have since 
persisted as a pathogen of public health concern. Despite this, there was a paucity of 
published epidemiological data on STEC cases in the UK and elsewhere. In 2009, 
Public Health England introduced an enhanced surveillance system for STEC 
collecting standardised and detailed microbiological, clinical and epidemiological 
data on all cases in England. Recent advances in microbiological methods for the 
detection and typing of STEC have occurred.  
 
In this thesis by published works, I use six publications utilising these methodological 
advancements. Together, these papers provide a detailed update on the 
epidemiology of STEC infection in England, including an assessment of the impact of 
molecular methods (PCR, MLVA and WGS), on our understanding and control of 
STEC. Specifically, I comprehensively describe the past and current epidemiology of 
STEC in England including clinical impact, and assess the impact of the recent 
introduction of advanced detection and typing techniques in England. The body of 
work as a whole provides a future perspective on where research is needed as well 
as informing operational implications for detecting and managing sporadic cases and 
clusters of infection.   
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Introduction 
The organism 
Vero cytotoxin-producing Escherichia coli (VTEC) were first recognised in 1977, 
following reports that some strains of E. Coli from cases of human and animal disease 
produced cytotoxin acting on Vero cells; hence the name Verocytotoxin.[1] Due to 
the similarity of the toxins to those in Shigella dysenteriae, VTEC are also known as 
Shiga toxin-producing Escherichia coli (STEC).For the work presented here, STEC 
nomenclature is used. 
While STEC belong to the wider group of Enterohaemorrhagic E. coli (EHEC), they are 
characterised by the possession of phage encoded shiga toxins (Stx (stx)), their main 
pathogenicity factors. Intimin (eae), involved in the intimate attachment of the 
bacteria to gut mucosa, is also an important factor in causing disease.  
The serogroup most associated with human disease in the UK is O157. Elsewhere, 
serogroups of STEC other than O157 (termed non-O157 STEC) have risen in 
prominence. Of particular note, was a large food-borne outbreak of STEC in Germany 
in 2011. The outbreak was caused by a novel strain of E. coli O104:H4 possessing 
Stx2a and intimin and caused 3,816 cases, 845 who developed Haemolytic Uraemic 
Syndrome (HUS) and 54 who died. [2] Elsewhere, Non-O157 strains are increasingly 
reported;  since 2013 in Ireland non-O157 STEC are reported to cause more human 
cases per annum than O157.[3] In the UK, due to a diagnostic bias for detection of 
O157, the prevalence and significance of Non-O157 STEC is unknown. 
Clinical significance 
Although relatively rare compared with other gastrointestinal infections, STEC 
infections are of significant public health concern due to the potential disease 
severity. Symptoms can range from mild diarrhoea to include abdominal cramps, 
vomiting and severe bloody diarrhoea (Haemorrhagic Colitis (HC)). Infection can lead 
to the development of HUS a severe multisystem syndrome clinically characterised 
by a triad of acute kidney injury, microangiopathic haemolytic anaemia and 
thrombocytopenia.  
Following ingestion of the bacteria, STEC enter the intestines and excrete the Stx 
toxin. These toxins enter the bloodstream via the gut mucosa, whereby they reach 
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target organs. Renal epithelium is enriched with receptors which Stx binds to 
resulting in the kidneys bearing the brunt of STEC toxicity. Extra-renal complications 
with HUS can occur, most frequently neurological complications, such as seizures, 
reported in 13 - 38% of cases. [4-12] Rarely, HUS is fatal.  
The overall proportion of STEC cases which are hospitalised and go on to develop 
HUS is largely unknown.  A previous study undertaken on data collected in 2000 in 
England, estimated 38% of STEC O157 cases were hospitalised,[13] but no other 
population based estimates of hospitalisation due to STEC  have since been 
published. In some outbreaks, progression to HUS has been reported in 20% to 65% 
of cases [14-17].Using data from surveillance of STEC cases, estimates of HUS range 
between 6.1% to 7.9% cases, (13, 16, 17) and the last reported data in England 
(1992-4) estimated that 12% of STEC cases developed HUS. (14) 
Children are at greater risk and numerous studies indicate that children aged below 
five years most frequently develop HUS. [5-10, 12, 18-24]  
Risk factors for human infection 
During the early years of the emergence of STEC, outbreak investigations implicated 
meat and dairy products as sources of infection and STEC was first isolated from 
Cattle in England 1989. [25] Subsequently, numerous studies on livestock were 
undertaken and STEC was frequently isolated from cattle, sheep and goats, with 
cattle considered the main reservoir of STEC.[26, 27]  
Transmission to humans occurs through consumption of contaminated food or 
water, direct or indirect contact with infected animals or their environment and 
through person to person spread. Each transmission route can cause sporadic 
infection as well as outbreaks. STEC has a very low infectious dose and ingesting less 
than 100 organisms can cause illness.[28-31] The incubation period (between 
exposure and the occurrence of symptoms) is usually between one and eight days 
(commonly 3-4 days). 
While outbreak investigations provide valuable information on viable vehicles and 
sources of infection, elucidating risk factors for sporadic infections is challenging. 
Several analytical studies were undertaken in the early 1990s to ascertain risk factors 
for sporadic infection and each indicated contact with animal excreta in the 
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environment as a major risk factor.[32-34] The relative role of transmission routes, 
their current relevance and trends over time are unknown.  
Surveillance and epidemiology of STEC in England 
The first laboratory surveillance report for England was published in 1993, for the 
period 1989-1991 and described a continued increase in detection of STEC cases. The 
authors described the Stx2 toxin subtype as being more often associated with both 
HC and HUS, which was reported for 15% of STEC cases. The distinct seasonality of 
STEC, with most cases occurring in the warmer months of May to September was 
presented, a phenomenon observed in other countries in the Northern Hemisphere. 
The incidence was highest in children aged 1-4 years and decreased with each age 
group, increasing again in the over 85’s. Infection rates were higher in adult females, 
with females over 35 having twice the rate of STEC than males. Incidence varied by 
region, and was highest in the North of England. A further report was published for 
the period 1992-1994, and reiterated these findings. 
The last and only other surveillance publication for England and Wales covered the 
period 1995-1998.[35] Further increases in detection of STEC were noted, but 
otherwise the demographic and geographic distribution of cases remained the same.  
There had been no update on the national epidemiology of STEC since 1998. Testing 
of STEC was only performed on specimens from patients experiencing HC or HUS, 
which was extended to include all diarrhoeal specimens in 1997. This major change 
in screening criteria will have impacted on the measurable burden of STEC overall 
and by sub-groups and no assessment of the change was undertaken until the work 
presented here. Furthermore, these reports relied on data collected through 
laboratory referral forms, rather than through a surveillance system. This passive 
system is subject to incomplete and inaccurate data collection; age and sex were 
only available for 89-93% of strains submitted. Geographical regions were assigned 
based on sending laboratories and not patients’ residence. Foreign travel and 
reporting of HUS were not routinely collected and so figures presented were likely 
underestimated. No clinical data were collected to assess the burden of illness and 
no other data had been collected on the burden of STEC in terms of hospitalisation 
and death since the IID1 study in 2000.[13]  
15 
  
Changes in the incidence of infection, host characteristics and microbiological 
subtypes over time had not been examined and a timely review of the burden of 
STEC was needed. Further, aside from outbreak reports, assessment of risk factors 
among sporadic cases had not been made since the 1990’s and an up to date 
assessment on who is at risk of STEC infection and where the risks of infection lie in 
England was required. 
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Aims and Objectives 
Despite the continued emergence of STEC as a pathogen of public health concern 
over three decades, there was a paucity of published epidemiological data on clinical 
STEC cases from the UK and elsewhere. Recently advances in surveillance and 
microbiological methods pertaining to STEC in England have occurred. 
With this in mind, the aim of this body of work was to provide a detailed update on 
the epidemiology of STEC infection in England including assessing the impact of 
molecular methods on our understanding and control. To achieve this aim, the 
research had three objectives. 
These were: 
1. Characterising the population at risk of STEC and identifying where the risks 
of infection lie  
 
2. Identifying host and pathogen factors which influence clinical outcome  
 
3. Evaluating the impact of enhanced detection and typing methods on our 
understanding of the epidemiology and public health impact of STEC 
Six publications addressing these objectives are included for consideration.  
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Methods 
The National Enhanced Surveillance System for STEC (NESSS) was implemented on 1st 
January 2009, and collects standardised and detailed microbiological, clinical and 
epidemiological data on all STEC cases in England.  Using these data I analysed a large 
cohort of cases with respect to the epidemiology and clinical impact of STEC infection 
in Papers 1, 3 and 5 (Objectives 1-3).  Over the following years, novel molecular 
methods for the detection and typing of STEC were trialled and the inclusion of 
microbiological data in NESSS facilitated my assessment and evaluation of these 
methods and their impact upon our knowledge of clinical infection in England (Table 
1).  
Electronic Foodborne and non-foodborne gastrointestinal 
Outbreak Surveillance System (eFOSS) 
In 1992, Public Health England began standardized surveillance of general outbreaks 
of gastrointestinal disease. The methods are reported in detail elsewhere but briefly, 
local PHE units report standardised epidemiologic data on all outbreaks of 
gastrointestinal diseases [36].  
National enhanced surveillance system for STEC (NESSS) 
From 1st January 2009, local laboratories reported presumptive isolates of STEC to 
Health Protection Teams (HPTs), who undertook public health management of the 
cases as per guidelines.[37] Stool specimens from patients were sent to the local 
hospital laboratory where they were tested for the presence of STEC O157. Locally 
confirmed isolates were sent for confirmation and typing at Gastrointestinal Bacteria 
Reference Laboratory (GBRU), London, which provides the national reference service 
for STEC in England and Wales. If STEC O157 was not isolated from a patient with 
clinical symptoms indicative of STEC (e.g. a child with HUS), the specimen was sent to 
GBRU and tested for the presence of non-O157 STEC. In cases where a faecal 
specimen was unavailable a serum sample was sent for serological detection of E. 
coli O157.  
Case management by HPTs included taking a detailed case history for the seven days 
prior to illness using the VTEC Enhanced Surveillance Questionnaire (ESQ) (Appendix 
IV). These questionnaires were forwarded to the National Gastrointestinal Infections 
(GI) department and entered into a web-based database for inclusion in NESSS. On a 
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daily basis GBRU test results were imported into NESSS and reconciled with case data 
collected through the ESQ. Multiple isolates  were received for a number of infected 
cases (due to follow-up samples being taken for clearance). These results were 
reviewed and one isolate chosen to represent the case. This would be the first isolate 
confirming infection or the report with the most information. Cases were assigned 
epidemiological and microbiological case definitions as set out in Paper 1. 
A detailed description of the isolation and typing of STEC at GBRU including changes 
over time is provided in Paper 2. Molecular methods (Polymerase Chain Reaction 
(PCR), Multi Locus Variable Number Tandem Repeat Analysis (MLVA) and Whole 
Genome Sequencing (WGS)) were assessed through the work presented in this thesis 
and detailed methods are contained within the individual papers. 
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Table 1. Summary of key surveillance and testing activities 
utilised for the composition of this work 
Surveillance/Testing 
activity 
Time period 
in place1 
Time period 
analysed2 
Research 
objective(s) 
Papers 
Electronic Foodborne and 
non-foodborne 
gastrointestinal Outbreak 
Surveillance System 
(eFOSS) 
1992 to date 01/01/1992-
31/12/2012 
1 Paper 2 
National Enhanced 
Surveillance system for 
STEC in England  
01/01/2009- 
to date 
01/01/2009-
31/12/2012 
1-3 Papers 
1,3 and 5 
Multi-locus variable 
number tandem repeat 
analysis (MLVA) for typing 
of all STEC O157 isolates 
routinely 
01/05/2012- 
01/08/2015 
01/05/2012-
31/10/2012  
3 Papers 3 
and 4 
Phased implementation of 
Polymerase Chain Reaction 
(PCR) for Gastrointestinal 
Infections  (GI) at frontline 
hospital laboratories 
01/12/2013- 
to date 
01/12/2013- 2,3 Papers 5 
and 6 
Pilot study for whole 
genome sequencing(WGS) 
of STEC isolates by GBRU1  
01/04/2012-
31/03/2014 
01/05/2012-
31/12/2013 
3 Papers  
4,5 and 6 
1. This pilot study included sequencing a subset of genomes from 1983 through 
to 2014, although the work was undertaken from 1st April 2012 through to 
31th March 2014. 
2. For the analyses I undertook in the papers only. 
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Objective 1:  Characterising the population at risk 
of STEC and identifying where the risks of infection 
lie  
Introduction 
 
STEC infections are not evenly distributed amongst the population and some groups 
are more at risk of infection and severe disease. However prior to the published 
work undertaken here , the last surveillance publication for England and Wales 
covered the period 1995-1998 and presented limited data collected through 
laboratory surveillance.[35]  Changes in the incidence of infection, host 
characteristics and microbiological subtypes over time had not been examined. 
Defining risk factors for infection is also important. A small number of case control 
studies in the 1990s identified contact with animal excreta as an important risk 
factor for infection in Great Britain.[32-34] Analysing outbreak data collected 
between 1992 and 2002, identified two  distinct aetiologies for  
foodborne outbreaks of STEC O157 infection, relating to  milk and red meat 
products.[38]  However no review of outbreaks, including non-foodborne outbreaks, 
or consideration of changes in exposure risks over time had been undertaken in 
England.  
An in-depth review of those at risk of STEC and where risk factors of infection lie in 
England was therefore required. The introduction of the National Enhanced 
Surveillance System for STEC (NESSS) on 1st January 2009, afforded the opportunity, 
alongside outbreak surveillance, to address these gaps through the work undertaken 
in Papers 1, 2 and 5. 
Methods 
To provide a detailed national picture on clinical STEC infections and assess risks for 
infection, data from NESSS were described for the first time for a four year period in 
Paper 1. Incidence rates were calculated by age, gender, ethnicity, geographic 
region, and rurality of residential post-code. Comparisons of incidence were made 
between demographic groups through calculation of Incidence Rate Ratios (IRR). The 
age and gender distribution of STEC cases were compared to those of Salmonella 
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enterica and Campylobacter sp. Environmental exposures were examined for 
primary, domestic sporadic STEC cases. In Paper 2, a review of 30 years of outbreaks 
of STEC O157 in England and Wales was undertaken, including a description of the 
causes and settings of outbreaks and relative changes in those over time in order to 
define where risk factors for STEC lie. In Paper 5, a matched case-case study to 
compare exposures amongst non-O157 STEC cases to O157 cases was performed.   
Results 
In Paper 1, a total of 3,717 confirmed and probable STEC cases were reported with a 
crude incidence of 1.80/100,000 person years, varying by age, sex, ethnicity and 
region of residence. Incidence was highest among children aged 1 to 4 years 
(7.63/100,000 person-years), and declined with each subsequent age group reaching 
a trough in adults aged 20-59. Over 40% of cases were in children, compared to 7.0% 
of campylobacteriosis and 17.8% of salmonellosis cases. Females had a higher 
incidence of STEC than males (RR=1.24, p<0.001), but the difference was most 
prominent in adults aged 20-59 (RR=1.7, p<0.001). Incidence was higher in white 
ethnic groups as compared to non-white ethnic groups (RR=1.43, p<0.001). The 
highest incidence was in the Yorkshire and Humber region (2.48/100,000 person-
years) and lowest in London (1.04/100,000 person-years). Incidence of STEC was over 
four times higher among people residing in rural areas than urban areas (RR=4.39, 
p<0.001).  
A fifth of cases comprised known outbreaks and a further fifth of cases were travel 
related. Non-O157 cases appeared to be more often travel associated than O157 
cases (52·3% vs. 20·6%, P = 0·021). However, in Paper 5 non-O157 cases (n=69) were 
at increased odds (OR=3.29, p<0.001) of contact with farm animals.  
 
Amongst sporadic cases, exposure to farm animals and/or their faeces were 
associated with infection and were reported twice as often among cases living in 
rural areas than urban areas (p<0.001). Reported direct and indirect contact with 
farm animals/faeces increased significantly with increased rurality, in both farm 
settings (p<0·001) and non-farm settings (p<0·001). Where farm settings were 
reported, the majority (84.5%) of urban cases reported visiting an open farm or 
holidaying on a farm, whereas the majority (58.9%) of rural cases reported living, 
working or having access to a farm through relatives or neighbours.  
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In Paper 2, vehicles and settings were examined for 335 outbreaks reported between 
1982 and 2012. These comprised 3,107 cases, representing 17.4% of cases overall. 
The median size of an outbreak was five cases (range 2-252). Overall, food vehicles 
contributed the highest number of outbreaks and associated cases, although they 
decreased proportionately in the later period of analysis (table 2) .   
Thirty-six outbreaks were reportedly attributed to consuming contaminated meat, 
although most (66.7%) occurred prior to 2003 (n=24). The first implicated food 
vehicle in an outbreak in this study was raw potatoes in 1985, and six outbreaks 
associated with raw vegetables or salads were subsequently reported throughout 
the study period. The largest national outbreak of STEC in Great Britain in 2011, 
affecting 252 cases was linked to handling raw leeks and potatoes. Between 1983 
and 2002, 14/17 dairy related outbreaks were associated with raw milk or post 
pasteurisation contamination of milk products, but no dairy-related outbreaks were 
observed thereafter. 
Person to person spread as a transmission route in outbreaks increased over time; 
This appeared to be driven by outbreaks in child-care facilities occurring with 
increasing frequency, demonstrating that person to person transmission remains an 
important driver of outbreaks. The number of open farm outbreaks also increased.  
In the first 20 years of the study, 14 open farm outbreaks were reported. Between 
2003 and 2012, 31 petting farm outbreaks were reported, including an outbreak in 
September 2009, affecting 93 cases.   
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Table 2. Reported outbreaks of STEC O157 by transmission routes in England and Wales 1983-2002 and 
2003-2012. 
Time period 1982-2002 2003-2012 
Transmission route/ 
subgroup 
No. 
outbreaks 
% 
No. 
outbreak 
cases 
% 
No. 
outbreaks 
% 
No. 
outbreak 
cases 
% 
Person to person 42 24.4 332 22.9 51 31.3 444 26.8 
Hospital 5 2.9 33 2.3 1 0.6 4 0.2 
Care home 10 5.8 50 3.5 6 3.7 26 1.6 
Nursery 20 11.6 217 15.0 39 23.9 395 23.8 
Other person to 
person 7 4.1 32 2.2 5 3.1 19 1.1 
Animal Contact 21 12.2 115 7.9 44 27.0 313 18.9 
Foodborne 62 36.0 717 49.5 38 23.3 704 42.4 
Raw vegetables 5 2.9 70 4.8 2 1.2 263 15.9 
Meat1 24 14.0 280 19.3 12 7.4 283 17.1 
Dairy 17 9.9 229 15.8 0 0.0 0 0.0 
Other food 0 0.0 0 0.0 5 3.1 31 1.9 
Food vehicle 
unknown 16 9.3 138 9.5 19 11.7 127 7.7 
Waterborne2 8 4.7 58 4.0 6 3.7 53 3.2 
Other   0 0.0 0 0.0 2 1.2 17 1.0 
Unknown vehicle 39 22.7 226 15.6 22 13.5 128 7.7 
All outbreaks 172 100.0 1448 100.0 163 100.0 1659 100.0 
1. Meat outbreaks include handling and consuming undercooked or raw meat and consuming cooked products which have been contaminated. 
2. Waterborne outbreaks include drinking or swimming/paddling contaminated water. 
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Discussion 
 
Paper 1 provided a detailed update on the epidemiology of STEC in England, 
reporting on a large dataset of cases over a four year period. Collection of 
standardised information through an enhanced system increased the reliability of 
the data and provided a more accurate reflection of cases attributable to outbreaks, 
secondary transmission and travel compared to laboratory surveillance alone.  
As described, the crude incidence of STEC was relatively low, varying by age, gender, 
ethnicity and geographical area of residence. However, there is a diagnostic gap for 
STEC for two reasons. First, many people with enteric pathogens do not present to 
health-care and of those who do, only a proportion will have a specimen taken. Of 
those who do, only a subset will yield a pathogen at local laboratories which will be 
referred to GBRU for typing. Two investigations aiming to determine the true 
incidence of infectious intestinal disease (IID) in England were undertaken in 1993-96 
(IID1) and 2008-9 (IID2).[39, 40] IID1 estimated that only one in six people with IID 
presented to a GP. For STEC, IID2 estimated that for each laboratory confirmed case, 
seven go undetected in the community. Severe illness, recent foreign travel and 
lower socioeconomic status were all found to be associated with GP 
presentation.[41] Clinical specimens are likely therefore to reflect more severe 
disease or foreign travel in those with less severe disease. Second, frontline 
diagnostics exploit the Non Sorbitol-Fermenting (NSF) properties of STEC O157 and 
mean that Non-O157 STEC, which often ferment sorbitol are undetected by these 
methods and their prevalence in England is unknown. Incidence rates reported in 
Paper 1 can therefore largely be inferred as those for STEC serogroup O157 only.  
Children have long been established as at greatest risk of STEC infection and these 
data were consistent with previous reports from the UK and elsewhere. [35, 42-44] 
While overall incidence is likely under-estimated, as described above, national 
surveillance data may also suffer ascertainment bias which could impact upon 
incidence among different groups. Female adults and children could be more likely to 
present to health-care and provide a specimen emphasising the impact of disease in 
those groups. The age distribution for STEC was much more heavily skewed towards 
children than that for either Salmonella enterica or Campylobacter sp. However, 
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STEC disease is more severe in children and any bias may be amplified by the severity 
of their symptoms.  
The low infectious dose and propensity for person-to-person transmission in 
childcare facilities also increases risk in these age groups.[45-50] Environmental 
transmission routes are also important for STEC, more so than for S. enterica or 
Campylobacter sp; as children practice poorer hygiene than adults, they are more 
likely to acquire infection, which may also contribute to their higher incidence. The 
increased incidence from infants under one year to those aged one to four years may 
reflect this; infants under one are also less mobile and less exposed to contaminated 
environments. 
Higher incidence rates in females had been reported previously in England.[35, 44] 
However the reasons for this are unknown and the disparity was not apparent for S. 
enterica or Campylobacter sp. Host factors may place women at greater risk of 
severe symptoms and increase their likelihood of presenting to healthcare. [51] 
Alternatively, adult females may have different behaviours with regards to 
consumption, food handling and childcare increasing their risk of infection. Incidence 
rates in England were assessed for the first time by ethnicity (Paper 1), and were 
higher among those of white ethnicity than those of non-white ethnicity. 
Interpretation of these data are limited as ethnicity was only reported for 38·5% of 
cases and ethnicity categories were broad. Collecting more detailed ethnicity data 
would enable these differences to be explored in more detail, ideally alongside other 
markers known to impact health outcomes such as socioeconomic status. 
The highest incidence rates were reported in the Northern and Western regions, 
while cases were more likely to live in rural than urban areas. Further work to assess 
the regional distribution of STEC infections accounting for rurality alongside other 
factors, such as livestock density is needed to elucidate this relationship. The 
increased risk associated with rurality and the wide geographical variations in 
incidence observed across the UK and Ireland appear to reflect environmental 
exposure to STEC in areas where ruminants are raised.[43, 52-56] Cases living in rural 
areas were over twice as likely to have had contact with livestock as those from 
urban areas. These findings demonstrate that environmental/animal contact is an 
important risk factor for infection amongst sporadic cases. Farm exposures differed 
between urban and rural cases, with the former being exposed more often to open 
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farms and rural cases to private farms. Open farms have the potential to cause 
outbreaks,[14, 57] and guidance exist around control of infection in those 
settings.[58, 59] The findings demonstrate however, that private farms are a 
significant driver in the burden of sporadic STEC infection and represent an 
uncontrolled risk.   In Paper 1, non-O157 cases appeared to be more often travel 
associated than O157 cases. However in Paper 5, which included an additional subset 
of Non-O157 cases in an adjusted analysis demonstrated that non-O157 cases were 
at increased odds of contact with farm animals suggesting the domestic animal 
reservoir is a driver for infection. In both studies non-O157 case numbers were small 
and these finding should be interpreted with caution. 
The sustained importance of person-to-person transmission, food-borne infection 
and zoonotic transmission in outbreaks over time was demonstrated in paper 2. 
However, there were apparent changes in settings and vehicles over time. Outbreaks 
occurring in prisons, hospitals and care-homes declined while outbreaks in schools 
and nurseries increased. This may suggest improved infection control measures in 
residential institutional settings, and historical examination of outbreaks of other 
pathogens would provide further insight into this. The apparent increase in 
outbreaks in child-care facilities may be reflective of increased child-care utilisation 
over the period, with more children accessing nurseries and therefore a larger 
population is at risk, although it was not possible to evaluate this. It is of concern 
that shifts in the settings of outbreaks have been towards those affecting children, 
the group most vulnerable to severe disease. 
Outbreaks associated with unpasteurised dairy products, post pasteurisation 
contamination, or pasteurisation failures which were prominent up to the early 
2000’s were not reported after 2002. Following a large outbreak in Wales in 2005 
due to cross contamination of meat supplied to schools which led to a public inquiry, 
meat related outbreaks were subsequently rarely detected. The decline in their 
occurrence suggests that efforts to reduce risk in catering, retail and meat hygiene 
sectors were effective.   
Outbreak surveillance data are reliant on correct detection of outbreaks and 
outbreak cases. A proportion of outbreaks reported were attributed to an unknown 
source, but some may have represented a coincidental occurrence of unrelated cases 
which did not have a common source. Alternatively, epidemiological links between 
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related cases may have been diluted through including unrelated cases in 
investigations, hampering the identification of source. Individual outbreak 
investigations were not evaluated in this work but may have been subject to 
potential investigation biases towards known risk factors for STEC, which will have 
changed over time following high profile outbreaks. For example, the first reports of 
STEC in the USA linked the pathogen to hamburgers and it was nicknamed the 
‘burger bug’. In England, handling raw vegetables was the first implicated vehicle in 
an outbreak, and the vehicle linked to the biggest national outbreak, in 2011, [60, 
61]yet vegetable sources were seldom reported in the intervening years.  
 
Interpreting outbreak data over time is subject to some limitations, as prior to 1998, 
only outbreaks of HC or HUS would have been detected. In the first report on STEC 
outbreaks published on eFOSS data, only 8% of STEC O157 cases in 1992-1994 were 
attributed to outbreaks. [62] If specific subtypes are associated with different 
vehicles and can cause more severe disease, than a preponderance to detect 
outbreaks of more severe disease may have biased identification of certain sources 
of infection. This is plausible based on the description of niche strain type, such as 
PT8 and travel in Paper 1. Despite these caveats, Paper 2 indicates that the 
prominent vehicles in outbreaks reported previously (contaminated meat and milk) 
no longer apply to the same extent and efforts to reduce risk need to be focused 
elsewhere.  
 
Impact and implications 
The risk of STEC infection in the population is unevenly distributed; women, children 
and those living in rural areas are at a greater risk of infection through a likely 
combination of host factors and behaviours which expose them to infection. Paper 1 
provided a foundation for further work, describing the distribution of disease and 
identifying areas for further exploration and has been cited by 18 articles. The finding 
that adult females are at greater risk is unexplained and warrants further 
investigation using robust, analytical studies accounting for other a priori risk factors. 
Expanding such studies to include a valid measure of ethnicity and socioeconomic 
variables to greater understand the uneven distribution of disease is needed.  The 
studies demonstrate that living in rural environments and exposure to animals and 
their environment is associated with sporadic infection. However, both surveillance 
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of animal populations and exploration of the interaction of humans with these 
environments are needed if interventions are to be considered.   
 
The analysis of outbreaks highlighted that microbiological risks in the food chain may 
change but persist to the extent that transmission of STEC over time is sustained. 
Since the study period an outbreak associated with raw drinking milk occurred in 
2014,[63] and one associated with unpasteurised cheese in  Scotland, causing a child 
death,  occurred in 2016(unpublished data). Additionally, outbreaks associated with 
salad vegetables have increased in frequency and size, and fit the profile of common 
PTs which are nationally dispersed, which would have been undetected using the 
previous criterion.[64-66]  These outbreaks highlight the continued, yet dynamic, 
microbiological risk from contaminated products and the importance of monitoring 
trends in consumption preferences which can impact upon foodborne infection risks. 
Efforts should focus on assessing microbiological risk in foods and proactively 
tackling biosecurity risks which can lead to contamination of ready to eat produce as 
well as increasing public awareness regarding risk. 
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Objective 2: Identifying host and pathogen factors 
which influence clinical outcome  
Introduction 
 
In outbreaks, progression to HUS has been reported to vary from 20% to 65% of 
cases [14-17]. Few countries monitor HUS at a population level, but Scotland, the US 
and Denmark report estimates of 6.1%, 6.3% and 7.9% respectively.(13,16,17) In 
England, the last reported data at a national level (1992-4) estimated that 12% of 
STEC cases developed HUS.[44]  However, these data were from a period when 
specimens  from cases of HC or HUS only were screened for STEC which will have 
likely accounted for the greater estimate than the other countries.[67]   
The risk of progression to HUS following STEC infection is heterogeneous and 
children are at greatest risk with numerous studies reporting that children aged 
below five years most frequently develop HUS. [5-10, 12, 18-24] STEC strains 
encoding the Stx2 toxin, particularly the Stx2a subtype more often cause HUS than 
other strains [68-72].  
 
The proportion of STEC cases which develop HUS overall and by sub-groups in 
England was unknown. The routine collection of clinical data reconciled with 
microbiological results for STEC cases through NESSS enabled me for the first time, to 
examine clinical severity, including development of HUS among STEC cases in Papers 
1 and 5.  
 
Methods 
Clinical data collected from NESSS were described , including the frequency of cases 
being hospitalised, developing HC or HUS overall and  by case demographic, STEC 
serogroup, STEC O157 phage type (PT), and Stx type. Comparisons were made 
between microbiological subtypes (PT and serogroup) and clinical presentation 
using Fisher’s exact test to assess statistical signiﬁcance (P < 0·05). In Paper 5, the 
pathogenicity traits of a set of Non-O157 strains were described including subtyped 
stx genes, and eae and aggR genes (additional pathogenicity factors). To assess for 
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associations with HUS, comparisons were made between groups and Fisher’s exact 
test used to assess statistical significance. Mantel– Haenzel odds ratios (ORs) were 
calculated to compare the risk of developing HUS within different groups.  
 
Results 
In Paper 1, clinical data were available for 3,267 symptomatic confirmed STEC 
cases, as well as 92 probable cases (confirmed serologically but STEC was not 
isolated). Diarrhoeal symptoms were indicated for 92·8% (3,117) cases, including 
HC for 61·0% (2,050). Abdominal pain was frequently reported (79·2%, 2,662), 
while fever (32·5%, 1,092), nausea (46·6%, 1564) and vomiting (37·3%, 1,252) 
were reported less often. Hospitalisation was recorded for 34·3% (1,151) and 
development of HUS for 6·4% (215) of cases. Thirteen deaths were reported, 
although cause of death was unknown; Nine were female and all but one were 
adult cases with a mean age of 65 years (95% CI 52·7–77·3). 
 
Disease severity differed by age, gender and strain characteristics. For most age 
groups, HC and hospitalisation were similarly reported for both sexes.  Three 
quarters of HUS cases were children aged 0–14 years, with a mean age of 14·6 
years (95% CI 11·7– 17·5). HUS was more frequently reported in females 
than males in both children and adults aged over 60. The highest proportion 
of STEC cases progressing to HUS was 15% in females aged 1–4 years.    
 
The most commonly detected serogroup was O157, accounting for 3,558 
(98·8%) of cases and just nineteen different non-O157 serogroups comprising 
44 cases were detected. Thirty-six different phage types (PTs) were isolated from 
cases with STEC O157 infection. The most common overall were PT21/28 and PT8, 
which contributed between 54·1% and 6 9 . 2 % of STEC O157 each year. Phage type 
8 was more often isolated in cases who had travelled abroad whereas PT 21/28 
cases appeared to be most often domestically acquired. 
 
Among STEC O157 cases, vomiting was more frequent in cases of PT21/28 than PT8 
(40·1% vs.  34·2%, P = 0·0078). Hospitalisation rates were higher (41·7% vs. 29·3%, P 
< 0·001), as was progression to HUS (8·5% vs. 1·1%, P < 0·001). PT2 was also 
associated with more severe disease than PT8, including vomiting (43·8% vs. 34·2%, P 
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= 0·015), hospitalisation (43·8%, P < 0·001), and progression to HUS (7·6%, P < 0·001). 
Clinical data were available for 42/44 non-O157 STEC cases and eighteen (42.8%) 
were reported to have developed HUS; Progression to HUS was therefore reported 
ten times more frequently in non-O157 cases than O157 cases (P < 0·001). Clinical 
presentation in non-O157 cases did not differ signiﬁcantly by presence of eae 
although numbers were small. Isolates from all cases of conﬁrmed STEC-HUS 
encoded stx2; 139 stx2 only, and 23 stx1 and stx2. 
 
In Paper 5, 97 non-O157 isolates from 84 cases were analysed. The most common 
non-O157 STEC serogroup detected was O26 (23.2%).  Forty-five (46.4%) isolates 
encoded stx2 only, 28 (28.3%) carried stx1 and stx2, and the remaining 24 (24.2%) 
stx1 only. The most frequently detected stx2 subtype was stx2a (64.0%).  The eae 
gene was detected in 50 (51.5%) non-O157 STEC isolates.  Six strains of STEC O104 
had aggR, another pathogenicity factor, but it was not detected in any other STEC 
strains.  Clinical data were available for 74 cases and 66 reported diarrhoea including 
HC in 35 cases (47.3%). A total of 28 (37.8%) of cases were hospitalised, similar to 
that reported in Paper 1. A quarter of cases (n=18) developed HUS. Children had the 
greatest odds of developing HUS (OR 4.4, p=0.005), but there was no difference by 
gender (OR 1.14, p=0.800). The development of HUS was significantly associated 
with STEC strains possessing eae (OR: 5.845, p=0.023) and/or stx2a (OR: 9.56, 
p=0.003).   
In Paper 1, an additional 115 cases of HUS were identified in NESSS without 
evidence of STEC, including three who died: 87 cases had only submitted serum 
samples which were negative for antibodies to E. coli O157 and no specimen was 
received by GBRU for 13 cases. For 15 HUS cases stx-negative E. coli were 
isolated, including four strains possessing eae. A gender disparity was also 
observed in these HUS cases with 55·7% being female. Compared to STEC 
confirmed HUS cases, a signiﬁcantly higher proportion of cases were adults 
aged over 60 years (20·0% vs. 7·9%, P = 0·007), with a mean age of 25·5 years 
(95% CI 20·5–30·5).  
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Discussion 
 
In Paper 1, reporting of both microbiological and questionnaire data was complete 
for over 97% of STEC infections reported, providing a large, comprehensive dataset 
of STEC cases for analysis while the analysis of additional data on non-O157 strains 
(Paper 5), allowed further exploration of strain pathogenicity for these serotypes,  
rarely detected in England. The clinical burden of STEC infection was high with 61% 
of symptomatic cases experiencing HC, over a third of cases hospitalised and 6.4% 
cases reported as developing HUS. The greatest burden in terms of severity lay in 
children consistent with the literature.  An excess of female cases under 15 and aged 
over 60 developed HUS. A number of previous studies have reported an excess of 
female HUS cases [9, 18, 19, 73-75], and in some a statistically significant association 
with female gender and developing STEC-HUS was found. [19, 73, 74].  However, an 
increased risk of HUS and female gender is unexplained, and may suggest host 
factors placing females at greater risk of developing HUS. In other studies no 
association between female gender and developing HUS has been demonstrated 
after adjusting for other factors, [7, 23, 75-77] and female gender did not correlate 
with HUS in Paper 5, although the study size was much smaller. 
 
Among cases of STEC O157, severity of illness varied by PT. Vomiting, hospitalisation 
and progression to HUS were all significantly more frequently reported among cases 
of PT 21/28 and PT2, compared to PT8 and all other PT's. As described in Paper 2, PT 
and Stx are interrelated; most (93.2%) PT8 strains possess stx1+2, whereas PT2 and 
PT21/28 usually possessed stx2 only. STEC O157 strains possessing stx2 only were 
therefore associated with increased progression to HUS. Among cases with HUS, all 
of the strains isolated encoded either stx2 only (85.8%) or stx1 and stx2 (14.2%). 
Cases of PT 21/28 and PT2 cases appear to be largely domestically acquired, 
suggesting the greatest burden of severe disease is due to domestic acquisition and 
is where interventions should be targeted.  
 
The frequency of specific GI symptoms of STEC infection did not differ among non-
O157 cases compared to O157 cases but hospitalisation rates and development of 
HUS were significantly higher in Non-O157 cases in Paper 1. This was expected as 
specimens are only sent for testing for Non-O157 STEC if there is clinical suspicion of 
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HUS, as per the national guidelines.  When the pathogenicity of non-O157 strains 
was assessed in Paper 5 which included additional isolates detected by a GI PCR 
(Paper 5) development of HUS occurred less often, with no HUS cases infected with 
strains detected via the PCR. This study was based on just three laboratories 
undertaking PCR and was too small to draw conclusions on the overall public health 
impact of non-O157 STEC in England. However, developing HUS was significantly 
associated with eae positive and/or strains encoding stx2a, consistent with other 
studies. (74-76) 
 
A further 115 cases of HUS, including three fatalities, were reported to NESSS 
without microbiological evidence of STEC Infection, representing  35% HUS cases 
captured by the system. Most (75.7%) had only submitted serum samples for testing 
which were negative for antibodies to E.coli O157. The gender composition of these 
HUS cases (55.7% females) was similar to all STEC cases. However, the mean age of 
these cases was significantly higher with a high proportion of adults aged over 60 
years. This may be due to low clinical suspicion of STEC-HUS in the adult population 
or a different prodrome reducing the opportunity for sampling and testing of faecal 
specimens and warrants further investigation. If a gender disparity exists and is 
specific to adults, it may be that an under-ascertainment of adult HUS cases is 
obscuring the association between females and development HUS in some studies 
and further investigations are needed. 
 
The data used are subject to some limitations. It is likely that HUS, hospitalisation 
and death were under-reported through NESSS; ESQs are completed to ensure that 
public health action is taken and represent the status of the patient at the time of 
completion. Half of cases were still ill when the questionnaire was administered, and 
were not followed up to determine subsequent outcome of their infection. The 
extent of the under-estimation of HUS through NESSS is unknown. 
 
Impact and implications 
 
Papers 1 and 5 have been referenced in the literature, with 20 citations each. They 
have provided a foundation for further work examining factors influencing disease 
severity; a subsequent multivariable analysis was undertaken on the data included in 
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Paper 1, for which I was second and corresponding author.[78]  This study 
demonstrated that being aged 1-4 years, female, infected with  PT21/28 and PT2 
strains, and prescription of antibiotics were significant predictors for developing 
HUS.  To explore further the role of stx subtypes I undertook a multivariable analysis 
to assess which STEC O157 lineages and stx subtypes are most associated with 
severe disease.[79]   
  
Further monitoring of non-O157 STEC is needed to better ascertain their impact in 
England and identify specific strains of public health concern. It is also important to 
monitor STEC O157 subtypes over time as changes in circulating strains may impact 
on the overall clinical burden of disease. Ascertainment of HUS using current systems 
is limited and better data capture would enable more accurate estimates of the 
burden of disease, including further studies to examine gender and HUS and to 
estimate HUS in the adult population.  
 
An HUS surveillance system or outcome surveillance as employed in a small number 
of countries would facilitate this. This could involve a bespoke system and/or linkage 
of NESSS with routinely collected data such as Hospital Episode Statistics. Such 
surveillance activities would be timely given the implementation of frontline PCR to 
detect non-O157 STEC and would allow better characterisation of the pathogenicity 
of non-O157 STEC strains, ultimately aiding with public health prioritisation of 
specific circulating STEC strains. 
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Objective 3: Evaluating the impact of enhanced 
detection and typing methods on our 
understanding of the epidemiology and public 
health impact of STEC 
Introduction 
This section considers the impact of newer technologies to subtype O157 STEC, to 
detect non-O157 STEC, and to subtype non-O157.  
 
Differentiating strains through typing methods is important for outbreak detection 
and investigation.  
In England, subtyping of STEC O157 includes differentiation by PT and Stx type. Since 
the early 2000’s the majority (~60%) of STEC O157 isolates detected in England 
belong to one of two phage types (Papers 1 and 2). For Non-O157 isolates, 
Serogroup and Stx type only were determined and strains weren’t  further 
differentiated. The ability to discriminate between cases from the same or a separate 
source is therefore low, and reliant upon applying the person-place-time paradigm to 
detect outbreaks and inform case definitions. It is likely that outbreaks of common 
types go undetected, particularly when cases are dispersed geographically and/or in 
time. This under-ascertainment is supported by the data, with just two national 
outbreaks detected in the thirty-years, 1983-2012.  
 
Between 2012 and 2014, molecular methods for detecting Non-O157 strains (GI PCR) 
were partly implemented, while MLVA was used to type isolates of STEC O157 and 
WGS was evaluated for STEC.  The reconciliation of the resultant microbiological data 
sets with NESSS facilitated an evaluation of these methods and their impact upon our 
knowledge of clinical infection, as presented in Papers 3-6.  
Methods 
From 1st May 2012, all confirmed STEC O157 isolated in England were subject to 
MLVA typing and I undertook a study (Paper 3) on the first six months of data to 
retrospectively assess the impact of this approach on the detection of clusters of 
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disease, which could represent outbreaks.  Cases were assigned as being part of a 
community cluster, household cluster or sporadic infection using MLVA and 
compared to the same cases categorised using existing methods for defining cases as 
related- a combination of monitoring PT and geographical and temporal links 
between cases.. The epidemiological data supporting a common link between cases 
in community clusters detected by MLVA were assessed. 
In Paper 4, whole-genome sequencing (WGS) was assessed for its ability to identify 
linked cases. Isolates were randomly selected from a sample of STEC O157 strains 
processed by GBRU in 2012 and 2013, as well as historical isolates selected from 
1990 and 2011 to represent the diversity of PTs seen in England and to provide 
population context. The SNP differences between isolates with a known 
epidemiological link were calculated to determine a threshold for defining related 
cases, termed the Common Source Threshold (CST).Clustering of cases over time 
within the CST were compared with clustering using an identical or SLV MLVA profile 
by survival analysis to compare the ability of the two methods at prospectively 
clustering cases together in time. Survival represented not clustering and failure 
represented clustering with another case. Both linking with a single other case and 
complete resolution of a cluster were assessed. 
 
In Paper 5, I describe the impact of the introduction of a frontline PCR on detecting 
non-O157 STEC. WGS for typing of non-O157 STEC isolates to discriminating 
outbreaks from sporadic infection was used in Paper 6, the description of an 
outbreak of O26 alongside results from WGS and metagenomic analysis were 
included.  
Results 
In paper 3, isolates from 556 confirmed cases of STEC O157 were differentiated into 
16 different PTs, most (62.8%) of which were PT21/28 or PT8 (n=349). Further typing 
by MLVA was undertaken on 539 isolates, and differentiated them into 341 unique 
(>2 locus variants) MLVA profiles.  The concurrence between MLVA and PT was high 
with three instances where the same MLVA profile covered more than one PT.  
 
Of the 341 unique MLVA profiles, 258 were uniquely observed for single cases only, 
representing sporadic infections. The other 83 were reported in clusters of >1 case: 
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42 due to known household transmission and 41 profiles shared amongst cases 
outside of the same household (community clusters). Of the 41 community clusters, 
21 had already been detected and investigated through existing methods- 
recognition of shared epidemiological links and a common PT. Almost twice as many 
community clusters were detected therefore using MLVA as compared to standard 
practices to detect outbreaks. .This included re-categorisation of 101/267 apparently 
sporadic, domestic infections as part of community clusters, reducing the proportion 
of sporadic cases in the dataset from 69% to 43%.  For the twenty clusters detected 
using MLVA only, most (n=18, 90%), of these clusters were of the two most common 
PT’s, PT21/28 and PT8. The cluster sizes were small with a median of three cases. 
Additional evidence of a link between cases was found in 12/20 clusters, four with 
shared exposures identified on ESQs and eight comprising cases occurring 
contemporaneously. Eight clusters comprised cases with no additional linkage 
beyond MLVA and were dispersed geographically and in time, with cases spanning 
several months. 
 
In Paper 4, 572 isolates from known outbreaks, linked household cases, multiple 
isolates from the same patient, and apparently sporadic cases were sequenced. All 
183 isolates with a known epidemiological link to another isolate had <5 SNPs 
difference from their epidemiologically linked isolates. The mean difference was one 
SNP between isolates from the same household, a known outbreak or isolates from 
the same case. This led to the hypothesis that a threshold of 5 SNPs could be used to 
detect outbreaks of STEC O157 and was termed the CST. This threshold was applied 
to the dataset and identified 136 additional cases with no prior known 
epidemiological link, which fell within 5 SNPs of another case. The majority (87%) of 
these pairs were strains which had been isolated within 30 days of each other with a 
mean of 11 days. Twenty of 33 WGS clusters were not previously detected, but were 
those identified in Paper 3 using MLVA. WGS did not link any additional cases which 
MLVA hadn’t and both methods were equally as sensitive. 
 
Clustering isolates over time using the CST was compared to MLVA (an identical or 
SLV MLVA profile). There was no significant difference based on clustering a single 
isolate with another (log-rank test for equality of survivor function: P = .101; Cox 
hazard ratio = 0.89, P = 0.198), indicating no difference in timeliness of clustering 
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cases between the two methods. However, when time to completion of the cluster 
was considered (i.e. all cases in the cluster are identified), WGS was more timely than 
MLVA (Cox HR=1.44, p=0.001). This is because MLVA typing can rely on an 
intermediary isolate appearing in the dataset to link two isolates which may 
themselves be two or more loci apart.  
 
In Paper 5, three frontline hospital laboratories implemented the GI PCR approach 
during the study period resulting in a significant increase in the detection of non-
O157 STEC; In 2013, 42 (42.4 %) non-O157 STEC isolates were detected compared 
with a total of 57 in the preceding 4 years (2009–2012), (P<0.001). In total, 22/97 
(22.7%) cases were detected by the three frontline laboratories using GI PCR. One 
hospital laboratory in London, the region with the lowest STEC incidence in England, 
reported 19 confirmed non-O157 cases during the first 12 months of adopting the GI 
PCR approach, while only five STEC O157 isolates were reported over that same 
period. This laboratory had previously reported three non-O157 cases between 2004 
and 2012. 
 
In Paper 6, 19 strains of E. coli O26:H11 were retrospectively sequenced including 
isolates from an outbreak to evaluate its utility in differentiating strains of this 
serogroup. WGS indicated that the nursery outbreak strains fell within 0-3 SNPs of 
each other. The outbreak included a case for whom faecal specimens were PCR 
positive for stx2 and eae but STEC O26:H11 was not cultured. Metagenomics 
undertaken on the faecal specimen from that case and provided molecular evidence 
that the strain she was infected with was related to the nursery outbreak. The 
phylogenetic relationship of the 19 sequenced strains indicated two sequence types 
using MLST, one denoting stx positive strains and the other stx negative strains. Of 
the latter, 2/3 of the cases had severe disease and one developed HUS. 
 
Discussion 
In Paper 3, MLVA provided a more discriminatory typing tool than phage typing, 
identifying almost twice as many clusters than by PT, redefining the relative burden 
of sporadic infection and that to a shared source. The clusters only identified through 
MLVA were more geographically and temporally dispersed and most belonged to the 
most common PTs. It is in unsurprising they went undetected therefore and supports 
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the supposition that national outbreaks occur undetected in the absence of fine 
typing techniques, including MLVA and WGS. These more discriminatory typing 
schemes enable a more specific definition of the population of sporadic cases and 
analysis of exposures using these case definitions would provide a more accurate 
characterisation of risk factors for sporadic infection and better inform risk 
assessment and targeted public health intervention.  
 
Retrospectively applying the person-place-time paradigm provided additional 
support to link the cluster cases in some of the MLVA identified clusters, but there 
were still those where   no additional available evidence supported a link to a 
common source. The same clusters were identified using WGS in Paper 4, providing 
reassurance that MLVA was as specific as WGS for this dataset and that these 
weren’t falsely detected clusters. The ESQ may not capture the detailed information 
often required to definitively link cases to a shared exposure. In Papers 3 & 4, the 
clusters were retrospectively reviewed and prospective investigation may have 
helped identify a common source through further interviewing. However, as most 
clusters were small the chance of identifying a source is reduced and analytical 
studies are not possible.  Alternatively, clusters dispersed in time could reflect repeat 
sampling of the reservoir of STEC infection over time- indicative of attribution rather 
than outbreaks per se.   
 
The survival analysis in Paper 4 indicated that there was no difference in clustering 
one case with another related case by method, but with WGS the cluster completes 
quicker. This is because all linked cases fall within the CST for all cases, whereas with 
MLVA several isolates will only be joined via an intermediate isolate (i.e. Double 
Locus Variants (DLVs) shared by a Single Locus Variant (SLV)) as shown graphically in 
paper 3. This means prospectively defining microbiological case definitions for 
outbreak investigations from the start is problematic using MLVA and what may 
appear as separate clusters or sporadic cases may later resolve as a single cluster if 
intermediaries are detected.  
 
A further consideration in interpreting the results of Paper 3 is a later analysis 
comparing the number of locus variants against the CST determined that 42% of 
strains related by a DLV using MLVA did not fall within the CST (unpublished data, 
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2014). An identical or SLV MLVA profile was a proxy for the CST in absence of 
additional epidemiological data, in 99.1% of instances. It was due to these results 
that in Paper4, the survival analysis comparing clustering dynamics for WGS and 
MLVA included isolates within an SLV only. However, there was concurrence 
between the clusters detected and the cases comprising them between the two 
analyses in Papers 3 and 4 despite the different MLVA loci thresholds used. Paper 4 
provided evidence that a threshold of within an SLV for clustering cases provides the 
same sensitivity as the WGS CST, giving confidence to laboratories not ready to 
adopt WGS technologies and that compared to PT, MLVA provides considerable 
advantages as a typing tool. 
 
Evaluation of PCR (Paper 5) showed that almost four times as many Non-O157 
isolates were detected via PCR than through culture and these were from 
laboratories in regions with the lowest STEC incidence in England. The ability for 
rapid detection of Non-O157 STEC is important for public health; In Paper 6, the first 
case, and subsequent outbreak, were detected through the referral of a stool 
specimen for further investigation to GBRU. Direct PCR on the stool identified stx 
genes and STEC O26 was subsequently isolated. Two weeks elapsed between onset 
of symptoms to reporting of STEC. If the PCR had been available at the frontline 
laboratory than diagnosis and management of STEC could have been more rapid, 
offering clear benefits in preventing onwards transmission in outbreaks.  
 
However, this would require taking action based upon a PCR positive result alone 
which raises issues in itself; the increased sensitivity of the PCR leads to PCR-positive 
but culture-negative results which are difficult to interpret with respect to risk of 
transmission and clinical significance. STEC O26, the causative strain in the nursery 
outbreak, as well as serogroups O103, O111 and O145, were already associated with 
more severe disease and known to cause HUS. However, the potential resource 
impact for public health follow-up and investigation of cases following further 
expansion of the GI PCR more widely is clearly large and various other strains were 
found which may or may not be of significant public health concern.  
 
The increase in detection of non-O157 strains highlighted a requirement to 
differentiate cases of non-O157 STEC. As described in papers 1-4, PT, MLVA and WGS 
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have been specifically used to type STEC O157 strains.  Paper 6 trialled the 
retrospective use of WGS for typing Non-O157 isolates for an outbreak for the first 
time in England and demonstrated that WGS provided highly discriminatory 
confirmation of linkage at the molecular level. While the serotyping and stx typing 
alongside the epidemiological links were strong enough evidence at the time to 
regard the cases as linked, we demonstrated for the first time that WGS can provide 
rapid and robust confirmation of relationships between STEC O26 strains. 
 
Impact and implications of the work  
 
The increased detection of clusters of STEC has resource implications for local and 
national public health teams. Alongside further prospective evaluation, the analyses 
in Papers 3 & 4, were used to inform an algorithm developed and implemented by 
PHE, for responding to clusters. This involves using a threshold of detecting five or 
more linked cases before initiating further investigations beyond review of the ESQs. 
This is to balance the additional demands of detecting many more clusters and the 
likelihood of identifying a common source. This was implemented when routine 
MLVA was in use in 2014 and continued when MLVA was superseded by WGS in 
2015. Adapted approaches have been adopted within PHE’s GI department to 
respond to clusters of  other GI pathogens. They are also of interest to international 
colleagues, and Papers 3 and 4 have been cited by 13 and 48 publications 
respectively. Paper 4 provided the forerunner to further investigating the interaction 
between phylogenetic and epidemiological relationships for STEC infections overall 
and in informing outbreaks, which I have continued to contribute to in my work.[65, 
80]  
 
The literature on the significance of Non-O157 STEC is relatively sparse and the 
numbers reported are often small. With 20 and 13 citations respectively, Papers 5 
and 6 have contributed to this field. Building on this, I have also undertaken further 
work examining the role of the stx and eae genes as predictors of severity rather 
than serotype and guidance for a differential public health response by PHE to Non-
O157 STEC based on host factors and the pathogenicity profile of the strains is 
currently under development.[79] 
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Conclusions 
Together the papers included meet the aim of the research and provided a detailed 
update on the epidemiology of STEC infection in England, including an assessment of 
the impact of molecular methods (PCR, MLVA and WGS), on our understanding and 
control of STEC.  In achieving this, I used the systematic collection of data by GBRU 
over three decades, augmented with the introduction of NESSS in 2009, outbreak 
surveillance since 1992 and the recent introduction of advanced detection and typing 
techniques in England to comprehensively describe the past and current 
epidemiology of STEC in England, evaluate clinical impact and assess the impact of 
the recent introduction of advanced detection and typing techniques in England. The 
body of work as a whole provided a future perspective on where research is needed 
as well as operational implications for detecting and managing sporadic cases and 
clusters of infection.   
The epidemiology of STEC infections in England was described using current 
surveillance methods and provided an update on the incidence of STEC, burden, risk 
factors and trends over time. The risk of STEC infection in the population was 
unevenly distributed; women, children and those living in rural areas were at greater 
risk of infection. The analysis of outbreaks highlighted that microbiological risks in 
the food chain may change, and despite several interventions over the decades, 
persist to the extent that transmission of STEC over time was sustained. With regards 
to disease severity, an increased risk of HUS amongst females was highlighted while 
the greatest burden of severe disease was found to be due to domestic acquisition. 
These studies were undertaken on routinely collected surveillance data. Analysis of 
such data provides a cost-effective and rapid solution to address research questions. 
The collection of standardised information on STEC through a national system, 
unique to the UK, provided a large and comprehensive dataset for analyses. The 
increased reliability of detailed, standardised enhanced data provided a more 
accurate reflection of cases attributable to outbreaks, secondary transmission and 
travel compared to laboratory surveillance alone. However, surveillance is subject to 
a number of ascertainment biases which could impact upon findings and their 
interpretation; cases detected are likely to reflect those with more severe disease 
which limits the generalisability of some results, and doesn’t capture the extent of 
mild or asymptomatic infection. While it was possible to examine risk exposures 
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amongst cases, and undertake a case-case analysis, examining risk factors for STEC 
infection overall was not possible due to the absence of a control population. A case-
control study would be a robust method to assess risks for STEC infection. 
The assessments of disease severity made using surveillance data were limited in 
that clinical definitions were not used and the timeliness of patient interviews meant 
that clinical outcome could not be reliably assessed. Indeed, since these papers, I 
have undertaken a paediatric cohort study of HUS which demonstrated that HUS is 
under-ascertained in NESSS and development of HUS is actually reported in as high 
as 25% in some groups (manuscript in preparation). The publications did however 
provide a foundation for further work examining factors influencing disease severity; 
a subsequent multivariable analysis was undertaken on the data included in Paper 1, 
for which I was second and corresponding author.[78]  This study demonstrated that 
being aged 1-4 years, female, infected with  PT21/28 and PT2 strains, and 
prescription of antibiotics were significant predictors for developing HUS.  I also 
collaborated with a PhD student who has undertaken a study using NESSS and the 
paediatric cohort data to examine risk factors for developing HUS, including markers 
of socioeconomic status (manuscript under submission).  
To explore further the role of stx subtypes I undertook a multivariable analysis to 
assess which STEC O157 lineages and stx subtypes are most associated with severe 
disease. This along with Paper X have been used as an evidence base to inform an 
algorithm and national guidelines on public health follow up of cases of Non-O157 
STEC, due to be published in 2018. In 2018, I have obtained access to Hospital 
Episodes Statistics (HES) data to link the data with NESSS to better understand the 
clinical burden of STEC infections by host and pathogen factors. This will be 
particularly important for gaining knowledge on the impact of Non-O157 strains and 
evaluating the public health guidelines which recommend reduced follow-up 
compared to O157.  
. 
Molecular techniques, which can rectify some of the limitations to surveillance (i.e. 
capturing Non-O157 data), were evaluated in this work .In summary together, Papers 
3-6 demonstrate the utility of new molecular methods, including PCR, MLVA and 
WGS at enhancing STEC surveillance activities. PCR rapidly detects cases of STEC 
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Non-O157 which previously went undetected. The public health importance of these 
strains was difficult to ascertain due to limited size of the datasets but the dataset 
now contains over 1200 cases of Non O157 STEC which I will be analysing in 2018. In 
parallel, MLVA and subsequently WGS have provided both more sensitive and 
specific detection of outbreaks and case definitions and redefined previous thinking 
on the relative burden of disease attributed to sporadic infection and outbreaks. 
However, these enhanced methods present challenges in terms of interpretation and 
workload.. This work has informed an algorithm developed and implemented by 
PHE, for responding to WGS clusters of GI disease. This involves using a threshold of 
detecting five or more linked cases before initiating further investigations beyond 
review of the ESQs. 
 
Paper 4 provided the forerunner to further investigating the interaction between 
phylogenetic and epidemiological relationships for STEC infections overall and in 
informing outbreaks, which I also continue to contribute to in my work at PHE as the 
lead surveillance scientist for STEC.  
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APPENDIX II: Co-authors statements of candidate’s 
contributions 
PhD by published work at University of Warwick Medical School 
Statement of contribution by Lisa Anne Byrne 
Paper to be used towards the PhD: 
Byrne L, Jenkins C, Launders N, R. Elson, Adak GK. The Epidemiology, microbiology 
and clinical impact of Shiga toxin-producing Escherichia coli in England, 2009-2012. 
Epidemiol Infect. 2015 Apr 29:1-13 
Study circumstances: This study was conducted to provide a recent and 
comprehensive update on the epidemiological distribution, microbiological 
characterisation and clinical impact of STEC infections in England. The study utilised 
data collected via an enhanced surveillance for STEC, newly introduced in 2009 and 
was the first paper describing these data.  The study was performed at Public Health 
England. Lisa Byrne was the epidemiological scientist responsible for the day to day 
management of national surveillance of STEC at the time of the study. 
Contribution: Lisa Byrne designed the study, managed and cleaned the data, 
performed descriptive and statistical analyses, led writing the manuscript in liaison 
with co‐authors and responded to reviewers as corresponding author. 
I agree that Lisa Anne Byrne made the contribution to the paper as stated above: 
Name Signature Date 
Claire Jenkins 
 
07-09-17 
Naomi Launders 
 
07-09-17 
Richard Elson 
 
08-09-17 
Goutam Adak 
 
08-09-17 
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PhD by published work at University of Warwick Medical School 
Statement of contribution by Lisa Anne Byrne 
Paper to be used towards the PhD: 
Natalie L. Adams, Lisa Byrne, Geraldine A. Smith, Richard Elson, John Harris,  Roland 
Salmon, Robert Smith, Sarah O’Brien, Goutam K. Adak, and Claire Jenkins. Shiga 
toxin-producing Escherichia coli (STEC) O157 in England and Wales. Three decades 
on, what has changed? Emerg Infect Dis. 2016 Apr;22(4):590-7 
Study circumstances: The study was carried out to provide a longitudinal review of 
STEC O157 infections across a thirty-year period since its emergence in the 1980’s. In 
the study, changes in microbiological testing over the period are described alongside 
the description and interpretation of trends in the number and microbiological 
subtype of infections. Outbreaks were reviewed across the time period and changes 
in vehicles and settings over time considered. The study was performed at Public 
Health England. Lisa Byrne was the epidemiological scientist responsible for the day 
to day management of national surveillance of STEC at the time of the study. 
Contribution: Lisa Byrne contributed to the study design and interpretation of data, 
extracted and cleaned outbreak data, wrote the outbreak section, drafted and 
critically revised the manuscript alongside co-authors. 
I agree that Lisa Anne Byrne made the contribution to the paper as stated above: 
Name Signature Date 
Natalie Adams 
 
08-09-17 
Geraldine Smith 
 
Richard Elson 
 
08-09-17 
John Harris 
 
07-09-17 
Roland Salmon 
 
08-09-17 
Robert Smith 
 
07-09-17 
Sarah O’Brien*   
Goutam Adak 
 
08-09-17 
Claire Jenkins 
 
07-09-17 
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PhD by published work at University of Warwick Medical School 
Statement of contribution by Lisa Anne Byrne 
Paper to be used towards the PhD: 
Byrne L, Elson R, Dallman TJ, Perry N, Ashton P, Wain J, Adak GK, Grant KA, Jenkins C. 
Evaluating the use of multilocus variable number tandem repeat analysis of Shiga 
toxin-producing Escherichia coli O157 as a routine public health tool in England. PLoS 
ONE 9(1): e85901. 
Study circumstances:  The study was carried out following an initial six-month period 
of routinely conducting multilocus variable number tandem repeat analysis (MLVA) 
on all STEC O157 strains isolated by the Gastrointestinal Bacteria Reference 
Laboratory in England.  The study aimed to evaluate the impact of this molecular 
method on the enhanced detection of clusters of infection and the defining of 
sporadic and linked cases, alongside consideration of other epidemiological factors 
linking cases. The study was performed at Public Health England. Lisa Byrne was the 
epidemiological scientist responsible for the day to day management of national 
surveillance of STEC at the time of the study. 
Contribution: Lisa Byrne designed the study, managed and cleaned the data, 
performed all descriptive and statistical analyses, led writing the manuscript in 
liaison with co‐authors and responded to reviewers as corresponding author. 
I agree that Lisa Anne Byrne made the contribution to the paper as stated above: 
Name Signature Date 
Richard Elson 
 
08-09-17 
Timothy Dallman 
 
14-09-17 
Neil Perry 
 
07-09-17 
Philip Ashton 
 
12-09-17 
John Wain*   
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Kathie Grant  11-09-17 
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PhD by published work at University of Warwick Medical School 
Statement of contribution by Lisa Anne Byrne 
Paper to be used towards the PhD: 
Dallman TJ,, Byrne L, Ashton P,, Cowley LA, Perry NT, Elson R, Adak GK, Underwood A, 
Green J, Jenkins C, Grant KA Wain J. Whole Genome Sequencing for National 
Surveillance of Shiga Toxin Producing Escherichia coli O157. Clin Infect Dis. 2015 Apr 
17.  
Study circumstances: This study was conducted in response to the advent, and 
planned implementation of WGS for analysing strains of enteric pathogens. The 
study aimed to assess the impact of WGS on detecting clusters of disease, determine 
a threshold for relatedness and compare it against existing typing methods. The 
study was performed at Public Health England. Lisa Byrne was the epidemiological 
scientist responsible for the day to day management of national surveillance of STEC 
at the time of the study. 
Contribution: Lisa Byrne (joint first author) led on the epidemiological aspects of  
study design, provided epidemiological context to clusters described; Conducted the 
evaluation of MLVA versus WGS including survival analysis and contributed to the 
drafting and critical revision of the manuscript. 
I agree that Lisa Anne Byrne made the contribution to the paper as stated above: 
Name Signature Date 
Timothy Dallman 
 
14-09-17 
Philip Ashton 
 
12-09-2017 
Lauren Cowley 
 
08-09-17 
Neil Perry 
 
07-09-17 
Richard Elson 
 
08-09-17 
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PhD by published work at University of Warwick Medical School 
Statement of contribution by Lisa Anne Byrne 
Paper to be used towards the PhD: 
Byrne L, Vanstone G. Perry N, Launders N, Adak GK, Godbole G, Grant K. Smith R., 
Jenkins C. The epidemiology and microbiology of Shiga-toxin producing Escherichia 
coli other than serogroup O157 in England 2009-2013. J Med Microbiol. 2014 
Sep;63(Pt 9):1181-8 
Study circumstances: From December 2012, a small number of frontline laboratories 
implemented a commercial PCR assay which directly detects the stx genes and can 
detect all STEC serogroups not just serogroup O157.  This study was conducted in 
response to the resultant increase in detection of Non-O157 STEC and described the 
characteristics of strains and compared disease severity amongst cases based on 
strain characteristics .The study was performed at Public Health England. Lisa Byrne 
was the epidemiological scientist responsible for the day to day management of 
national surveillance of STEC at the time of the study. 
Contribution: Lisa Byrne designed the study, managed and cleaned the data, 
performed all descriptive and statistical analyses, and wrote the manuscript in liaison 
with co‐authors. 
I agree that Lisa Anne Byrne made the contribution to the paper as stated above: 
Name Signature Date 
Gemma Vanstone*   
Neil Perry  07-09-17 
Naomi Launders  07-09-17 
Goutam Adak 
 
08-09-17 
Gauri Godbole 
 
11-09-17 
Katie Grant 
 
11-09-17 
Robin Smith*   
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PhD by published work at University of Warwick Medical School 
Statement of contribution by Lisa Anne Byrne 
Paper to be used towards the PhD: 
Dallman TJ, Byrne L, Launders N, Glen K, Grant KA, Jenkins C. The utility and public 
health implications of PCR and whole genome sequencing for the detection and 
investigation of an outbreak of Shiga toxin-producing Escherichia coli serogroup 
O26:H11. Epidemiol Infect. 2014 Oct 15:1-9.  
 
Study circumstances: An outbreak of non-O157 STEC in a nursery school was 
described in respect to the application of both PCR and WGS in investigations. The 
utility of these methods in real-time was demonstrated. The study was performed at 
Public Health England. Lisa Byrne was the epidemiological scientist responsible for 
the day to day management of national surveillance of STEC at the time of the study. 
Contribution: Lisa Byrne (joint first author) provided epidemiological input into the 
study design, provided the epidemiological context to the study and contributed to 
the drafting and revising of the manuscript. 
I agree that Lisa Anne Byrne made the contribution to the paper as stated above: 
Name Signature Date 
Timothy Dallman 
 
14-09-17 
Naomi Launders 
 
07-09-17 
Kirsten Glen 
 
07-09-17 
Kathie Grant 
 
11-09-17 
Claire Jenkins 
 
07-09-17 
*These co-authors have been approached for their attested statements but due to 
them being on leave were unable to provide them in the time needed for timely 
submission of this thesis. I will continue to communicate with them and expect to 
have all signatures for a subsequent, final version of the thesis 
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